U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

					Application Num	ber	10/5	22,660
TRANSMITTAL					Filing Date	_	Aug	ust 16, 2005
			FORM		First Named Inve	ntor	Rent	zeperis et al.
	(to be used	for all o	correspondence after in	itial filing)	Art Unit		1743	
					Examiner Name		Land	lsman, Robert S.
Tot	al Number o	f Pages	in This Submission	+ references	Attorney Docket	Number	3092	3-713.831
				ENCLOSU	RES (Check all that	apply)		
	Fee Trans	smittal	Form	☐ Drawin	g(s)			After Allowance communication to Technology Center (TC)
	Fee	e Attacl	ned .	Licensin	ng-related Papers			Appeal Communication to Board of Appeals and Interferences
	Amendm	ent/Rep	oly	Petition				Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
	After Final				to Convert to a onal Application			Proprietary Information
	Affidavits/declaration(s)			Power of Attorney, Revocation Change of Correspondence Address				Status Letter
	Extension	of Tin	ne Request	Terminal Disclaimer		\boxtimes	Other Enclosure(s) (please identify below):	
	Express A	Abando	nment Request	Request for Refund			Forms 08A and B	
\boxtimes	Informati	on Disc	closure Statement	CD, Number of CD(s)				references
				Lar	dscape Table on CD		<u> </u>	
	Certified Documen		f Priority	Remarks				
	Response Incomple		sing Parts/					
	-		to Missing Parts					
	unc	ler 37 (CFR 1.52 or 1.53	TYPE OF ARE	I ICANE APPORA	TWOD 1	GEN/A	
Firm N	In-	WILS	SON SONSINI GOO		LICANT, ATTORN	EY UR A	GENT	*
			mi 670					
Printed Name Samir Elamrani, Ph.D.								
Date			mber <u>9</u> , 2005			Reg. No.	43,601	
				CERTIF	ICATE OF MAILIN	īG		
I hereb	y certify that below.	t this paj	per is being E-filed to I			-	0, Alexar	dria, VA 22313-1450 on the date
Signat	ure		anis	igas				
Typed	or printed na	me	Ann Lygas	(10		Date	Decemb	per 9, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

L_] becaus		§1.97(b). This Information Disclosure Statement should be considered by the Office
		 It is being filed within 3 months of the application filing date of a national application and is other than a continued prosecution application under §1.53(d); OR
		(2) It is being filed within 3 months of entry of a national stage as set forth in §1.491 in an international application; OR
	\boxtimes	(3) It is being filed before the mailing date of the first Office Action on the merits; OR
		(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under §1.114.
	specific office a closes	§1.97(c). Although this Information Disclosure Statement is being filed after the period in 37 CFR §1.97(b), above, it is filed before the mailing date of the earlier of (1) a final tion under §1.113, (2) a notice of allowance under §1.311, or (3) an action that otherwise rosecution on the merits, this Information Disclosure Statement should be considered it is accompanied by one of:
		a certification as specified in §1.97(e) provided concurrently herewith; OR
		a fee of \$180.00 as set forth in §1.17(p) authorized below, enclosed, or included with the payment of other papers filed together with this statement.
	date of §1.311,	$\S1.97(d)$. Although this Information Disclosure Statement is being filed after the mailing the earlier of (1) a final office action under $\S1.113$ or (2) a notice of allowance under it is being filed before payment of the issue fee and should be considered because it is nied by:
	A.	a certification as specified in §1.97(e); and
	В.	a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this Statement.
	37 CF.	$\S1.97(e)$. A certification signed by an Attorney of Record is provided herewith as under 37 CFR $\S1.97(b)$ and (c).
\boxtimes	37 CFF	§1.98(a)(2). The content of the Information Disclosure Statement is as follows:
		Copies of each of the references listed on the attached Form PTO/SB/08A are enclosed nerewith.
	\boxtimes	Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08A are NOT enclosed.
	\boxtimes	AND/OR Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on
		the attached Form PTO/SB/08A are enclosed in accordance with 37 CFR §1.98(a)(2). AND/OR
		Copies of pending unpublished U.S. patent applications are enclosed in accordance with 17 CFR §1.98(a)(2)(iii).

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Rentzeperis et al.

Group Art Unit: 1743

Serial Number: 10/522.660

Examiner: Robert S. Landsman **CONFIRMATION NO: 8712**

Filing Date: August 16, 2005

Title: Method for the Identification of Ligands

Certificate of Mailing 37 CFR §1.8

I hereby certify that this paper is being E-filed to Mail Stop IDS, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450

Mail Stop IDS Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 81.97

Sir:

Applicants hereby submit an Information Disclosure Statement along with attached forms PTO/SB/08A. A copy of each listed publication is being submitted, if required, pursuant to 37 C.F.R. §§1.97-1.98, as indicated below.

Applicants respectfully requests that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached forms PTO/SB/08 in accordance with MPEP §609.

Applicants reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

	re Statement includes non-English patents and/or		
			ncise explanation of the relevance of each patent, d that is not in English is provided herewith.
		Pursuant to 37 CFR §1.98(a)(3)(ii), a coreference(s) is provided herewith	opy of a translation of the non-English language
\boxtimes	Attache	ed is a copy of the EP search report(s) from	m a corresponding patent application(s).
⊠	of \$0.0		y authorized to charge the above-referenced fees credit any overpayment associated with this (Docket No.30923-713.831
			Respectfully submitted,
			WILSON SONSINI GOODRICH & ROSATI
ے 650 Pa	ge Mill l	,	By: Sau Constant Samir Elamrani, Ph.D. Reg.No. 43,601

(650) 493-9300 Customer No. 021971

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitute fo	or form 1449	/PTO		Application Number	10/522,660		
INFORM	IATION I	DISC	LOSURE	Filing Date	August 16, 2005		
	STATEMENT BY APPLICANT			First Named Inventor	Rentzeperis et al.		
(Use as	many sheets	s as ne	cessary)	Art Unit	1743		
				Examiner Name	Landsman, Robert S.		
Sheet	1	of	2	Attorney Docket Number	30923-713.831		

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where			
Initials*	No.	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
	1	US-2002-048811	04-25-2002	Devreotes et al.				
		US-						
		US-						
		US-						
		US-						
		US-			,			

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
	2	WO-02-103321	12-27-2002	Anadys Pharmaceuticals, Inc.		
	3	WO-99-27365	06-03-1999	Tularik Inc.		П
	4	WO-97-42500	11-13-1997	3- Dimensional Pharmaceuticals, Inc.		
]				F

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USFTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-clutre code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitute f	or form 144	19/PTO)	Application Number	10/522,660		
INFORM	IATION	DISC	CLOSURE	Filing Date	August 16, 2005		
	STATEMENT BY APPLICANT			First Named Inventor	Rentzeperis et al.		
(Use	as many shee	ets as ne	cessary)	Art Unit	1743		
				Examiner Name	Landsman, Robert S.		
Sheet	2	of	2	Attorney Docket Number	30923-713.831		

Examiner Initials*	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.						
	5	GREENFIELD et al., "Increase in the Stability and Helical Content of Estrogen Receptor alpha in the Presence of the Estrogen Response Element: Analysis by Circular Dichroism Spectroscopy," Biochemistry 2001, 40, 6646-6652					
	6	ZHANG, Y. and ZHANG, Z., "Low-Affinity Binding Determined by Titration Calorimetry Using a High-Affinity Coupling Ligand: A Thermodynamic Study of Ligand Binding to Protein Tyrosine Phosphatase 1B ¹					
		·					
Examiner signature		Date Considered					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



P.B.5818 - Patentiaan 2 2280 HV Rijswijk (ZH) 22 (070) 3 40 20 40 FAX (070) 3 40 30 16

Europäisches Patentamt

European Patent Office Office européen des brevets

Generaldirektion 1

Directorate General 1

Direction générale 1

Vossius & Partner Siebertstrasse 4 81675 München ALLEMAGNE





EPO Customer Services

Tel.: +31 (0)70 340 45 00

Date

04.10.05

Application No./Patent No. PCT/US0229661 K3087 EP S3 02766306.1 - 2404 Applicant/Proprietor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

COMMUNICATION

The European Patent Office herewith transmits as an enclosure the supplementary European search report under Article 157(2)(a) EPC for the above-mentioned European patent application.

If applicable, copies of the documents cited in the European search report are attached.

Additional set(s) of copies of the documents cited in the European search report is (are) enclosed M as well.

Refund of the search fee

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.



SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application Number EP 02 76 6306

	DOCUMENTS CONSIDEREI		Delevent	OL 40015104710N OF 7115
Category	Citation of document with indication of relevant passages	n, wnere appropriate,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.C1.7)
Υ	WO 97/42500 A (3-DIMENS PHARMACEUTICALS, INC) 13 November 1997 (1997-	11-13)	2-4, 9-11, 16-18, 20-22, 24-26, 28-30, 36,39,40	
	* the whole document *			C07K7/00 C07K14/00
Υ	US 2002/048811 A1 (DEVR AL) 25 April 2002 (2002		2-4, 9-11, 16-18, 20-22, 24-26, 28-30, 36,39,40	C07K16/00 C07K17/00
	* the whole document *	· 		
X	GREENFIELD N ET AL: "I Stability and Helical C Receptor alpha in the P Estrogen Response Eleme Circular Dichroism Spec BIOCHEMISTRY, AMERICAN EASTON, PA, US, vol. 40, no. 22, 10 May pages 6646-6652, XP0029 ISSN: 0006-2960	content of Estrogen bresence of the contract Analysis by ctroscopy" CHEMICAL SOCIETY.	1,5-8, 12-15, 19,23, 27, 31-34,37	TECHNICAL FIELDS SEARCHED (Int.CI.7) G01N A61K C07K
Y	* the whole document *		2-4, 9-11, 16-18, 20-22, 24-26, 28-30, 36,39,40	
		-/		
X:pa Y:pa do A:tet O:nc P:int	The supplementary search report has set of claims valid and available at the	been based on the last start of the search. Date of completion of the search		Examiner
	Munich	22 September 200	5 Die	z Schlereth, D
X:pa Y:pa do A:te-	CATEGORY OF CITED DOCUMENTS inticularly relevant if taken alone inticularly relevant if combined with another cument of the same category chnological background nwritten disclosure termediate document	T: theory or princip E: earlier patent do after the filling da D: document cited L: document cited 8: member of the 8 document	cument, but pub- ite in the application for other reasons	lished on, or

SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application Number EP 02 76 6306

Category	Citation of document with interest of relevant passe W0 99/27365 A (TULAR 3 June 1999 (1999–06)	ges IK INC)	Pelevant to claim 2-4, 9-11, 16-18,	CLASSIFICATION OF THE APPLICATION (IntCI.7)
•	WO 99/27365 A (TULAF 3 June 1999 (1999-06	ik INC) -03)	9-11, 16-18,	
	* the whole document	. *	20-22, 24-26, 28-30, 36,39,40	
	*		1-40	
1	ligand: A thermodyna binding to protein to 18" ANALYTICAL BIOCHEMIS	by titration high—affinity coupling amic study of ligand cyrosine phosphatase		
	ISSN: 0003-2697 ∨ * the whole documen	/ t *		TECHNICAL FIELDS SEARCHED (Int.CI.7)
Ξ.	WO 02/103321 A (ANA INC) 27 December 20 * the whole documen	DYS PHARMACEUTICALS, 02 (2002-12-27) t * V	1-40	
				1
	The supplementary search repo set of claims valid and available	rt has been based on the last at the start of the search.		
	Place of search	Date of completion of the search		Examiner
	Munich	22 September 200	Die Die	z Schlereth, D
X:pa Y:pa do A:1ec	CATEGORY OF CITED DOCUMENTS inicularly relevant if taken alone tricularly relevant if combined with ano current of the same category chnological background nwritten disclosure	E : earlier patent d after the filing d her D : document cited L : document cited	in the application for other reasons	shed on, or

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

22-09-2005

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9742500	A	13-11-1997	AU AU CA EP HU JP KR NZ	3205097 2253587 0914608		22-11-2001 26-11-1997 13-11-1997 12-05-1999 29-11-1999 05-09-2000 25-02-2000 28-07-2000
US 2002048811	A1	25-04-2002	AU WO	1323402 0233102		29-04-2002 25-04-2002
WO 9927365	A	03-06-1999	AU AU CA EP JP JP	734875 1598999 2309879 1032834 3584211 2001524672	B2 A A1 A1 B2 T	21-06-2001 15-06-1999 03-06-1999 06-09-2000 04-11-2004 04-12-2001
WO 02103321	Α	27-12-2002	CA EP JP	2450641 1409982 2004537047	-	27-12-2002 21-04-2004 09-12-2004